Best of ASCO - 2014 Annual Meeting

 

Welcome

Chemotherapy

Developmental Therapeutics and Tumor Biology (Nonimmuno)

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A breakthrough in treatment of cancer patients with grade 4/profound febrile neutropenia.

Calin Ioan Cainap

e14513

A first-in-human study of, NUC-7738, a 3'dA phosphoramidate, in patients with advanced solid tumors or lymphoma (NuTide 701).

Hagen P Schwenzer

TPS3147

A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors.

Florence Atrafi

3026

A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A.

Antonio Jimeno

3032

A polymorphism within the mismatch repair gene predicts prognosis and adjuvant chemotherapy benefit in gastric cancer patients.

Deqiang Wang

3025

A pretreatment CT model predicts survival following chemolipiodolization in patients with hepatocellular carcinoma.

Dong Wu

e14509

Anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent.

Sarah Patricia Blagden

3030

Assessing the risk of chemotherapy toxicity and hospital admission due to toxicity.

Samuel Robert Malton

e14508

First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma.

Vincent Chung

TPS3146

PDX validation of a 3D microtumor platform.

Ellen Sampson

3029

Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial.

Jason D. Lickliter

e14514

Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced cholangiocarcinoma and solid tumors.

Filip Janku

3008

Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors.

Jaffer A. Ajani

3034

Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.

Dana Backlund Cardin

3031

Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with advanced solid tumors.

Nagla Fawzy Abdel Karim

3027

Prospective cohort study of the impact of hospital-wide dihydropyrimidine dehydrogenase (DPYD) genotype testing for fluoropyrimidine-based chemotherapy on adverse events and hospital costs.

Theodore John Wigle

3028

Rationale and preclinical development of LEAF-1401 and LEAF-1701: A novel class of potent next generation antifolates.

Victor M. Moyo

e14515

Risk of QTc interval prolongation among cancer patients treated with tyrosine kinase inhibitors.

Anan Abdelmoti Abu Rmilah

3033

The dynamic detection of drug area under curve (AUC) guides clinical usage of docetaxel in solid tumors.

Yan Zhang

3024

The influence of kinesin light chain-2 on the radiosensitivity of non-small cell lung cancer cells and the underlying mechanisms.

Shangbiao Li

e14512